🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

19 results for “Black” Clear

  1. Active Surveillance

    Black Diamond Therapeutics

    Muscle-Invasive Bladder Carcinoma

    phase 3 other active

    1 trial

  2. Placebo

    Black Diamond Therapeutics

    Parkinsons Disease (PD)

    phase 3 small molecule active

    1 trial

  3. PTH

    Black Diamond Therapeutics

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  4. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Black Diamond Therapeutics

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  5. silevertinib (BDTX-1535) monotherapy

    Black Diamond Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. silevertinib in combination with temozolomide

    Black Diamond Therapeutics

    Glioblastoma (GBM)

    phase 2 small molecule active

    1 trial

  7. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  8. ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL

    Ultragenyx UK Limited

    Latrodectism

    phase 1 small molecule completed

    1 trial

  9. Azathioprine 50Mg Tab

    Black Diamond Therapeutics

    Therapeutic Equivalency

    phase 1 small molecule completed

    1 trial

  10. BDTX-189

    Black Diamond Therapeutics

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  11. Levodopa

    Black Diamond Therapeutics

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  12. Liberase Enzyme (Roche)

    Black Diamond Therapeutics

    Pulmonary Alveolar Proteinosis

    phase 1 small molecule active

    1 trial

  13. Normal Saline (NS) .9% 10 mL Injection

    Black Diamond Therapeutics

    Ovarian Failure

    phase 1 small molecule active

    1 trial

  14. YF476

    Black Diamond Therapeutics

    Hypergastrinaemia

    phase 1 small molecule completed

    2 trials

  15. Chocolate PTA Balloon

    Black Diamond Therapeutics

    Atherosclerosis

    approved other active

    1 trial

  16. Liposomal bupivacaine

    Black Diamond Therapeutics

    Liposomal Bupivacaine

    approved small molecule active

    1 trial

  17. DGB-01 Supplementation

    Black Diamond Therapeutics

    Fatigue

    other completed

    1 trial

  18. Percutaneous Transluminal Angioplasty (PTA)

    Black Diamond Therapeutics

    Peripheral Artery Disease

    other active

    1 trial

  19. Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter

    Black Diamond Therapeutics

    Peripheral Artery Disease

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources